Ipilimumab vs Rituximab
Ipilimumab vs Rituximab: Overview
This comparison examines the pharmacological differences between Ipilimumab and Rituximab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Rituximab β 22 days.
Chemical Properties
Type: Ipilimumab β Antibody; Rituximab β Antibody.